Articles By Rob Wright, Chief Editor

2021_Rob Wright headshot
Be The Inspiration
The world is hurting. Now more than ever, people need and want to be inspired by people. Just imagine what we can accomplish if we all strive to be the inspiration we seek.  Continue Reading..
  • Building A COVID-19 Vaccine Company In A Few Months

    Mei Mei Hu, J.D., and her husband Lou Reese know what it’s like to develop a drug during a pandemic. Nearly 20 years ago they helped develop a vaccine and antibody test for the SARS outbreak. But now they were considering starting a COVID-19 vaccine company — during 2020.

  • How An Industry Outsider Became A Biopharma CEO

    John Fowler had never worked in biopharma before. That didn’t stop his best friend — a scientist — from asking Fowler to lead the biotech startup he had been working on. It was a risk to both the company’s future — and their friendship.

  • From Aha Moment To $10 Billion Biopharma

    In 2012 Neil Kumar, Ph.D. read an article in Nature Biotechnology and was so inspired by the paper’s theories on drug discovery and development, that he eventually decided to quit his job and start his own biopharma called BridgeBio.

  • Got Your Zoom On?

    The majority of my interviews have been over the phone. As for how many interviews for feature articles I’ve conducted via Zoom, the number is exactly two — both appearing in this issue.

  • How Has The Pandemic Impacted You — And Your People?

    Disruption of life routines by COVID-19 provide a CNS opportunity on multiple fronts. 

  • The Making Of A CFO — A Conversation With J&J’s Joseph Wolk

    Joe Wolk’s father spent 40 years working at the nearby J&J manufacturing facility. Now, Joe has reached the top of the organization as CFO. His path getting there, though, didn’t start in pharma.

  • The Streak — Is Over

    Our previous 16 regular issues of LSL (excluding the annual outlook issue) featured a biopharmaceutical company CEO on the cover. But our cover features aren’t limited to the CEO, as this month’s issue shows with our feature on J&J’s CFO Joe Wolk.

  • Is Biopharma's Reputation Back?

    While biopharma's response to COVID-19 has started to turnaround the industry's sagging reputation, one successful response to one crisis does not a reputation save.

  • Enanta Pharmaceuticals: From Failure To Formidable

    While working at a VC firm, Jay Luly, Ph.D., was tasked with assessing if Enanta Pharmaceuticals could be turned around, or if it should be shut down. Today the company is probably one of the most productive Big Pharma R&D engines you’ve never heard of — until now.

Rob Wright author page

Rob Wright

Rob Wright is the chief editor of Life Science Leader magazine. Prior to joining the publication, he spent nearly 20 years in the pharmaceutical industry. During his industry career, Wright conducted well over 1,000 presentations and roundtable discussions, including the facilitation of FDA-mandated clinical training programs for hundreds of licensed healthcare providers. He has chaired, moderated, and served as a speaker at industry and academic conferences, and served as co-chair for the 2015 and 2018 BIO International conference’s educational planning committee. Wright’s 500+ published articles have appeared in peer-reviewed academic journals, B2B magazines and online publications. He received a B.S. in Business Administration from Indiana University of Pennsylvania, MBA with distinction from Gannon University, and completed his doctoral coursework in marketing at Cleveland State University. He is a member of international business honor societies Sigma Beta Delta and Beta Gamma Sigma. He can be followed on Twitter @RfwrightLSL